Resverlogix Corp.
TSX:RVX.TO
Overview | Financials
Company Name | Resverlogix Corp. |
Symbol | RVX.TO |
Currency | CAD |
Price | 0.065 |
Market Cap | 18,070,000 |
Dividend Yield | 0% |
52-week-range | 0.04 - 0.1 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Donald J. McCaffrey |
Website | https://www.resverlogix.com |
An error occurred while fetching data.
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD